Immunocore/$IMCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunocore
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Ticker
$IMCR
Sector
Primary listing
Employees
493
Headquarters
Website
Immunocore Metrics
BasicAdvanced
$1.7B
-
-$0.41
0.77
-
Price and volume
Market cap
$1.7B
Beta
0.77
52-week high
$39.33
52-week low
$23.15
Average daily volume
313K
Financial strength
Current ratio
5.893
Quick ratio
5.601
Long term debt to equity
111.877
Total debt to equity
112.351
Interest coverage (TTM)
-1.63%
Profitability
EBITDA (TTM)
-24.559
Gross margin (TTM)
92.32%
Net profit margin (TTM)
-5.70%
Operating margin (TTM)
-7.97%
Effective tax rate (TTM)
9.07%
Revenue per employee (TTM)
$720,000
Management effectiveness
Return on assets (TTM)
-1.69%
Return on equity (TTM)
-5.43%
Valuation
Price to revenue (TTM)
4.702
Price to book
4.33
Price to tangible book (TTM)
4.33
Price to free cash flow (TTM)
58.858
Free cash flow yield (TTM)
1.70%
Free cash flow per share (TTM)
0.568
Growth
Revenue change (TTM)
26.78%
Earnings per share change (TTM)
-63.34%
3-year revenue growth (CAGR)
57.14%
3-year earnings per share growth (CAGR)
-47.90%
What the Analysts think about Immunocore
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Bulls say / Bears say
In 2024, KIMMTRAK net sales increased 30% year-on-year to $310.0 million, driven by Q4 sales of $84.1 million and marking 11 successive quarters of growth (Immunocore.com).
In Q1 2025, Immunocore generated $93.9 million in net product revenue, a 33% year-on-year increase, reflecting strong KIMMTRAK uptake in both the U.S. and Europe (Nasdaq).
In Q2 2025, KIMMTRAK net product sales rose 30% year-on-year to $98.0 million, with 15% growth in the U.S. and 71% growth in Europe and international regions, underscoring robust global expansion (GlobeNewswire).
Research and development expenses surged to $222.2 million in 2024, up 36% year-on-year, reflecting aggressive pipeline investment that heightens cash burn risk (Immunocore.com).
R&D spend climbed further to $69.0 million in Q2 2025 from $51.1 million a year earlier, intensifying pressure on profitability outside of KIMMTRAK sales (GlobeNewswire).
Selling, general and administrative costs rose to $155.8 million in 2024, up from $144.5 million in 2023, indicating elevated overhead that could erode margins if sales growth slows (Immunocore.com).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
Immunocore Financial Performance
Revenues and expenses
Immunocore Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunocore stock?
Immunocore (IMCR) has a market cap of $1.7B as of September 18, 2025.
What is the P/E ratio for Immunocore stock?
The price to earnings (P/E) ratio for Immunocore (IMCR) stock is 0 as of September 18, 2025.
Does Immunocore stock pay dividends?
No, Immunocore (IMCR) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next Immunocore dividend payment date?
Immunocore (IMCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunocore?
Immunocore (IMCR) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.